Clinical Study

How Effective and Safe Is Bronchial Thermoplasty in “Real Life” Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?

Rita Arrigo,1 Giuseppe Failla,2 Nicola Scichilone,1 Alba La Sala,2 Carla Galeone,3 Salvatore Battaglia,1 Alida Benfante,1 and Nicola Facciolongo3

1Dipartimento di Biomedicina e Medicina Specialistica, Sezione di Pneumologia, University of Palermo, Palermo, Italy
2Interventional Endoscopic Unit, ARNAS Ospedale Civico Di Cristina Benfratelli, Palermo, Italy
3Pulmonology Unit, Department of Cardiology, Thoracic and Vascular Surgery and Critical Care Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy

Correspondence should be addressed to Nicola Scichilone; nicola.scichilone@unipa.it

Received 20 June 2016; Accepted 24 August 2016

Academic Editor: Hiroto Matsuse

Copyright © 2016 Rita Arrigo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is limited information on the efficacy and safety of bronchial thermoplasty (BT) in real life. We evaluated the outcomes of the randomized clinical trials for BT in severe asthmatics, in whom the exclusion criteria were not strictly controlled. A case series of seven asthmatics (M/F: 4/3; age: 54.6 ± 2.9 years) is reported. Subjects had a statistically significant improvement in AQLQ (from a mean of 3.96 ± 1.1 to 4.5 ± 1.2 and 5.5 ± 0.6 after 6 and 12 months of treatment; \( p = 0.0007 \)) and in the ACQ score (from 2.77 ± 0.8 to 1.83 ± 1.2 and 1.5 ± 0.8 after 6 and 12 months; \( p < 0.001 \)). In the year after BT, severe exacerbations, salbutamol use, and OCS use were significantly lower compared with the 1-yr pretreatment period (\( p < 0.001 \)). No ED visits and hospitalization occurred in the year after BT. No changes in functional parameters were recorded. Our investigation confirms the safety and efficacy of BT in severe asthmatics in real life settings.

1. Introduction

Bronchial asthma is estimated to affect around 300 million people worldwide, with 5% to 10% of patients suffering from a severe form of the disease that is often refractory to usual treatment [1]. Although inflammation is the underlying mechanism in asthma, alterations of the airway smooth muscle (ASM) contraction represent the hallmark of the disease. ASM contraction is responsible for airway narrowing and airflow obstruction in asthma, and both hypertrophy and hyperplasia of the ASM cells might contribute to the difficulty in obtaining adequate control in some subjects with severe asthma, by causing airflow obstruction.

Treatment of severe asthma is based on the use of high dose of long-acting beta-2 agonists and inhaled corticosteroids (LABA/ICS), possibly associated with other interventions such as oral corticosteroids or anti-IgE treatment. The most recent edition of the GINA guidelines includes bronchial thermoplasty (BT) as a nonpharmacological, selective treatment of severe asthma [2]. BT is a novel intervention that delivers controlled thermal energy to the airway wall through a dedicated catheter during a series of bronchoscopy procedures that result in a prolonged reduction in ASM mass [3, 4], thus ameliorating the symptoms of asthma. Although BT is being increasingly employed in clinical practice, there is limited published information specifically addressing the efficacy and safety of BT in real life [5, 6]. We therefore attempted to evaluate the effectiveness of BT in a real life sample of individuals suffering from severe asthma undergoing the procedure, by assessing the same primary and secondary outcomes of the main randomized clinical trials for BT.

2. Methods

Eligible subjects were adults (18–65 years of age) diagnosed with severe symptomatic asthma according to the
Table 1: Clinical and lung functional characteristics of the study subjects. Exacerbations, ER visits, and hospital admissions were registered in the previous year.

| Subject | Age (yrs) | Gender | Severe exacerbations | ER visits | Hospital admissions | FEV\textsubscript{1} (% pred) | VC (% pred) | FEV\textsubscript{1}/VC |
|---------|-----------|--------|----------------------|----------|---------------------|-----------------|------------|---------------------|
| 1       | 55        | F      | 12                   | 12       | 1                   | 73              | 104        | 0.60                |
| 2       | 35        | M      | 2                    | 0        | 0                   | 67              | 66         | 0.45                |
| 3       | 58        | M      | 2                    | 0        | 0                   | 78              | 84         | 0.70                |
| 4       | 48        | F      | 2                    | 0        | 0                   | 77              | 87         | 0.69                |
| 5       | 69        | F      | 4                    | 6        | 6                   | 61              | 110        | 0.47                |
| 6       | 67        | M      | 6                    | 4        | 0                   | 80              | 122        | 0.63                |
| 7       | 50        | M      | 3                    | 0        | 0                   | 73              | 84         | 0.69                |

GINA guidelines [2], who required regular maintenance medications of inhaled corticosteroids (ICS > 500 mcg/day beclomethasone or equivalent) and a long-acting \( \beta \)-2-agonist (LABA > 100 mcg/day salmeterol or equivalent). Other medications were allowed, including leukotriene modifiers, omalizumab (if used for at least 1 year), anticholinergic drugs, and oral corticosteroids (OCS). Inclusion criteria were as follows: subjects on stable maintenance asthma medications for at least 4 weeks before entry, prebronchodilator FEV\textsubscript{1} > 60% of predicted value, and being a nonsmoker for at least 1 year with less than 10 pack-years of smoking history. The only exclusion criteria were the absolute contraindications to the BT: life-threatening asthma, respiratory diseases such as emphysema, use of anticoagulants, and prebronchodilator FEV\textsubscript{1} < 60% of predicted value.

Subjects were recruited from the Biomedical Department of Internal Medicine and Specialist (DiBiMIS), University of Palermo, Italy, the ARNAS Hospital of Palermo, Italy, and the Pulmonology Unit, Department of Cardiology, Thoracic and Vascular Surgery and Critical Care Medicine, Azienda Ospedaliera ASMN, Reggio Emilia, Italy. All subjects gave their written consent to the procedure and to the use of their clinical information for scientific purposes.

BT was performed by delivering radiofrequency energy to the airway using the Alair Bronchial Thermoplasty System and the Alair Catheter in 3 sessions, about three weeks apart, each lasting about 50 minutes, according to the international recommendations [7]. Subjects were evaluated 4 weeks before the first procedure and at 6 and 12 months after the last procedure. At each visit, physical examination, asthma-related quality of life (QoL) by the Asthma Quality of Life Questionnaire (AQLQ), asthma control by the Asthma Control Questionnaire (ACQ), rate of severe exacerbations (i.e., those requiring systemic corticosteroids or doubling of ICS dose), use of asthma medications, and changes in lung function, as well as adverse events, were assessed. Furthermore, emergency department (ED) visits, hospitalizations, days missed from work/school or other activities due to asthma, and rescue medication use were compared to the previous year.

3. Results

Seven asthmatics with poorly controlled asthma despite maintenance medical therapy including high dose inhaled corticosteroid (ICS) and long-acting \( \beta \)-2-agonist (LABA) were included (M/F: 4/3; age: 54.6 ± 2.9 years). Median dose of ICS was 2400 mcg/day beclomethasone or equivalent. Six out of 7 subjects were also under regular oral corticosteroids (OCS, median prednisone or equivalent: 48 mg/day). The functional characteristics of the study subjects are described in Table 1. Subjects showed a statistically significant improvement in AQLQ, which increased from a mean of 3.96 ± 1.1 to 4.5 ± 1.2 after 6 months of treatment and 5.5 ± 0.6 at 12 months (\( p = 0.0007 \)); in particular, 3 subjects reached the minimal clinically important difference of 0.5 at 6 months and 5 subjects reached it at 12 months. All treated subjects showed a statistically significant improvement in asthma symptom control: the ACQ score was 2.77 ± 0.8 before treatment and decreased to 1.83 ± 1.2 after 6 months (\( p = 0.008 \)) and to 1.5 ± 0.8 after 12 months (\( p = 0.001 \)); 4 subjects reached the minimal important difference at 6 months, whereas all subjects achieved it at 12 months. During the posttreatment period, a reduction in number of severe exacerbations compared with pretreatment periods of one year was documented (0.4 ± 0.8/yr versus 4.5 ± 3.6/yr). The OCS dose decreased from 10 ± 8 mg/day of prednisone or equivalent to 8 ± 6 mg/day after 6 months and to 4 ± 4 mg/day after 12 months of treatment (\( p = 0.03 \)). The salbutamol use, in terms of puffs/die, decreased from 1.86 ± 1.7 to 0.4 ± 0.8 after 6 months (\( p = 0.002 \)) and to 0.1 ± 0.4 after 12 months (\( p = 0.008 \)). The absence of ED visits and hospitalization was also documented in the year after BT (from a mean of 3 ± 4.5/yr and 1 ± 2/yr, resp.). The number of days missed from work dropped from 10.6 ± 7.5 in the year before BT to 1 ± 1.8 in the year after BT (\( p = 0.04 \)). As expected, we did not find any significant change in lung functional parameters, such as FEV\textsubscript{1}, VC, FEF\textsubscript{25}, FEF\textsubscript{50}, and FEF\textsubscript{75} (\( p > 0.05 \) for all analyses). No serious adverse events were recorded, except for a case of lung atelectasis from fibrin plug, which resolved rapidly [8].

4. Discussion

Bronchial thermoplasty is a new FDA-approved treatment of patients with severe asthma; this treatment was developed in order to improve the quality of life and symptom control in patients with severe asthma, consequently reducing the costs associated with the disease. The current observational study aimed to assess the effects of BT in real life, evaluating patients who had already completed the treatment for at least one
The present study has the advantage of having included (and treated) subjects whose comorbid conditions would have been exclusion criteria for the clinical trials, such as chronic sinus disease, gastroesophageal reflux, history in the previous year of three or more hospitalizations for asthma, three or more lower respiratory tract infections, and four or more pulses of OCS use for asthma. If anything, the extension of inclusion criteria reinforces the effectiveness of BT. It can also be speculated that although the study did not include an economic evaluation, these findings likely translate into reductions of direct and indirect costs for asthma [10].

In summary, the current real life observational study confirms that BT is an effective and safe treatment for severe asthma, even in subjects with high number of exacerbations and/or comorbidities. These findings support the implementation of this procedure in severe symptomatic asthmatics.

Competing Interests
The authors declare that they have no competing interests.

References

[1] J. Bousquet, E. Mantzouranis, A. A. Cruz et al., “Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma,” Journal of Allergy and Clinical Immunology, vol. 126, no. 5, pp. 926–938, 2010.

[2] Global Strategy for Asthma Management and Prevention, 2016, http://ginasthma.org/.

[3] M. Castro, A. I. Musani, M. L. Mayse, and N. S. Shargill, “Bronchial thermoplasty: a novel technique in the treatment of severe asthma,” Therapeutic Advances in Respiratory Disease, vol. 4, no. 2, pp. 101–116, 2010.

[4] M. Pretolani, M.-C. Dombret, G. Thabut et al., “Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 12, pp. 1452–1454, 2014.

[5] D. C. Doeing, A. K. Mahajan, S. R. White, E. T. Naureckas, J. A. Krishnan, and D. K. Hogarth, “Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series,” Journal of Asthma, vol. 50, no. 2, pp. 215–218, 2013.

[6] S. Bicknell, R. Chaudhuri, N. Lee et al., “Effectiveness of bronchial thermoplasty in severe asthma in ‘real life’ patients compared with those recruited to clinical trials in the same centre,” Therapeutic Advances in Respiratory Disease, vol. 9, no. 6, pp. 267–271, 2015.

[7] K. F. Chung, S. E. Wenzel, J. L. Brozek et al., “International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma,” European Respiratory Journal, vol. 43, no. 2, pp. 343–373, 2014.

[8] N. Facciolongo, F. Menzella, M. Lusuardi et al., “Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report,” Multidisciplinary Respiratory Medicine, vol. 10, no. 1, article 9, 2015.

[9] M. Castro, A. S. Rubin, M. Laviolette et al., “Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 2, pp. 116–124, 2010.

[10] M. J. Cangelosi, J. D. Orteundahl, L. M. Meckley et al., “Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 15, no. 2, pp. 357–364, 2015.